WO2017142052A1 - アミノ酸含有組成物 - Google Patents

アミノ酸含有組成物 Download PDF

Info

Publication number
WO2017142052A1
WO2017142052A1 PCT/JP2017/005825 JP2017005825W WO2017142052A1 WO 2017142052 A1 WO2017142052 A1 WO 2017142052A1 JP 2017005825 W JP2017005825 W JP 2017005825W WO 2017142052 A1 WO2017142052 A1 WO 2017142052A1
Authority
WO
WIPO (PCT)
Prior art keywords
fatigue
amino acid
lipid metabolism
containing composition
food
Prior art date
Application number
PCT/JP2017/005825
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
悠一 津田
山口　真
佳緒里 岩澤
Original Assignee
株式会社明治
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社明治 filed Critical 株式会社明治
Priority to CN201780011660.1A priority Critical patent/CN108697679B/zh
Priority to JP2018500217A priority patent/JP6942113B2/ja
Publication of WO2017142052A1 publication Critical patent/WO2017142052A1/ja
Priority to HK18114133.9A priority patent/HK1255012A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Definitions

  • the present invention relates to an amino acid-containing composition for anti-fatigue and / or for promoting lipid metabolism.
  • ⁇ Fatigue associated with exercise is a phenomenon that everyone is experiencing, and an increase in fatigue results in a decrease in motivation for exercise and / or a decrease in exercise performance.
  • the degree of fatigue is larger than that in healthy people, and a decrease in motivation to exercise and / or a decrease in exercise performance appears significantly. Therefore, moderate exercise is effective in preventing and / or improving obesity and / or metabolic syndrome.
  • Patent Document 1 describes a fatigue recovery or nourishing tonic containing a proteolytic peptide obtained by degrading a protein-containing raw material with a thiol protease derived from germinated soybeans and a serine protease derived from a microorganism.
  • Patent Document 2 discloses an amino acid nutritional composition having an early recovery effect on human muscle fatigue, comprising arginine, isoleucine, leucine, valine, lysine, methionine, threonine, histidine, proline, phenylalanine, tryptophan, and glutamine. Is described. Furthermore, Patent Document 3 describes an amino acid composition for a fatigue inhibitor comprising 6 to 12 amino acids of proline, glycine, alanine, lysine, tryptophan, histidine, threonine, tyrosine, arginine, valine, leucine and isoleucine. Has been.
  • Patent Document 4 fatigue prevention comprising proline, alanine, glycine, valine, threonine, leucine, histidine, serine, lysine, isoleucine, glutamic acid, arginine, methionine, L-carnitine, and coenzyme Q10 (hereinafter referred to as CoQ10).
  • An amino acid composition having an anti-obesity effect by promoting lipid metabolism as well as reduction and recovery is described.
  • Patent Document 5 describes a lipid metabolism promoter containing arginine, phenylalanine and alanine.
  • JP 2005-239579 A Japanese Patent Application Laid-Open No. 08-198748 WO2007 / 145239 JP 2008-255033 A JP 2016-102064 A
  • an object of the present invention is to solve the problems of the prior art as much as possible, and to provide economically and rationally an amino acid-containing composition having a high anti-fatigue effect and / or a lipid metabolism enhancement effect.
  • the present inventor has paid attention to arginine, valine, and serine in an intensive study in order to solve the above-mentioned problems.
  • An amino acid-containing composition containing only these three amino acids has a high anti-fatigue effect and / or lipid.
  • the present invention has been completed.
  • this invention consists of the following content.
  • An anti-fatigue amino acid-containing composition comprising an amino acid as an active ingredient, wherein the amino acids are arginine, valine and serine.
  • Arginine is 50 to 70% by weight, 25-50% by weight of valine, The anti-fatigue amino acid-containing composition according to any one of [1] to [3], wherein serine is 0.1 to 15% by weight.
  • An anti-fatigue agent comprising the amino acid-containing composition for anti-fatigue according to any one of [1] to [4].
  • An anti-fatigue food or drink comprising the anti-fatigue amino acid-containing composition according to any one of [1] to [4].
  • a packaged anti-fatigue food or drink comprising the anti-fatigue amino acid-containing composition according to any one of [1] to [4].
  • An anti-fatigue and lipid metabolism-enhancing amino acid-containing composition comprising an amino acid as an active ingredient, wherein the composition is arginine, valine and serine.
  • Arginine is 50 to 70% by weight, 25-50% by weight of valine, The amino acid-containing composition for anti-fatigue and lipid metabolism enhancement according to any one of [8] to [10] above, wherein serine is 0.1 to 15% by weight.
  • An anti-fatigue and lipid metabolism-promoting agent comprising the anti-fatigue and lipid metabolism-promoting amino acid-containing composition according to any one of [8] to [11].
  • An anti-fatigue and lipid metabolism-promoting food or drink comprising the anti-fatigue amino acid-containing composition according to any one of [8] to [11].
  • a container-packed food and drink for anti-fatigue and lipid metabolism enhancement comprising the anti-fatigue amino acid-containing composition according to any one of [8] to [11].
  • [6] The amino acid composition according to [1] or [2], containing arginine at 50 to 70% by weight, valine at 25 to 50% by weight, and serine at 0.1 to 15% by weight.
  • [10] A method for preventing or suppressing fatigue, wherein the amino acid composition according to any one of [1] to [6] is taken before and / or during exercise.
  • a method for preventing or suppressing fatigue and enhancing lipid metabolism which comprises ingesting the amino acid composition according to any one of [1] to [6] before and / or during exercise.
  • an amino acid-containing composition having a higher anti-fatigue effect with fewer kinds of amino acids and also having a lipid metabolism enhancing effect was obtained. It is expected that an amino acid-containing composition, food and drink, etc. can be provided economically and rationally.
  • FIG. 1 is a graph showing the amount of change in blood cortisol concentration measured in Example 4.
  • the present invention relates to an anti-fatigue and / or lipid metabolism-enhancing amino acid-containing composition
  • an amino acid as an active ingredient wherein the amino acids are (1) arginine (2) valine and (3) serine.
  • preferred contents of the amino acids (1) to (3) are as follows.
  • the content is shown as the content relative to the total weight of the amino acids (1) to (3).
  • the content of arginine in the present invention is preferably 50 to 70% by weight based on the total weight of amino acids of arginine, valine, and serine. If the content of arginine is 50% by weight or more, the anti-fatigue effect and / or the lipid metabolism enhancing effect of the present invention is exhibited, which is preferable. Moreover, it is preferable that the content of arginine is 70% by weight or less, since an anti-fatigue effect and / or a lipid metabolism enhancing effect derived from valine other than arginine and serine are further exhibited.
  • the content of valine in the present invention is preferably 25 to 50% by weight based on the total weight of arginine, valine and serine. If the content of valine is 25% by weight or more, the anti-fatigue effect and / or lipid metabolism enhancing effect of the present invention is exhibited, which is preferable. Moreover, if the content of valine is 50% by weight or less, it is preferable because an anti-fatigue effect and / or a lipid metabolism enhancing effect derived from arginine other than valine and serine are further exhibited.
  • the serine content in the present invention is preferably 0.1 to 15% by weight based on the total weight of arginine, valine and serine.
  • a serine content of 0.1% by weight or more is preferable because the anti-fatigue effect and / or lipid metabolism enhancing effect of the present invention is exhibited.
  • a serine content of 15% by weight or less is preferable because an anti-fatigue effect and / or a lipid metabolism enhancement effect derived from arginine other than serine and valine are further exhibited.
  • amino acids (1) to (3) preferred contents are as follows.
  • the content is shown as the content relative to the total weight of the amino acids (1) to (3).
  • the content of arginine is 50 to 70% by weight
  • the content of valine is 25 to 50% by weight
  • the content of serine is 0.1 to 15% by weight. It is preferable.
  • the content of each amino acid is within the above range, the anti-fatigue effect and / or the lipid metabolism enhancing effect are remarkably exhibited.
  • the total content is 100% by weight.
  • “fatigue” refers to a state in which fatigue, fatigue, muscle pain, muscle tension, and / or a decrease in exercise performance have occurred due to an exercise load. Therefore, “anti-fatigue” refers to preventing or suppressing fatigue, fatigue, muscle pain, muscle tension, and / or a decrease in exercise performance.
  • the anti-fatigue effect can be evaluated by measuring a blood biomarker during exercise.
  • the blood biomarker for example, blood glucose level, corticosterone, cortisol, lactic acid, ammonia, creatine kinase, lactate dehydrogenase, TGF- ⁇ and the like can be used.
  • the evaluation by blood biomarker measurement is performed by, for example, exercise load by forced swimming, treadmill or the like for two groups of administration group (administration of amino acid-containing composition) and non-administration group (non-administration or administration of water). It can be evaluated by giving a simulated state of exercise by administration of adrenaline, etc., collecting blood after a lapse of a certain time, measuring the concentrations of blood biomarkers in the two groups, and comparing the measured concentrations.
  • the blood glucose level is reduced by consumption of carbohydrates due to continued exercise, and the exercise performance is also reduced accordingly. It can be evaluated that the anti-fatigue effect is more effective than the administration of water.
  • corticosterone, cortisol, lactic acid, ammonia, creatine kinase, lactate dehydrogenase, and TGF- ⁇ are increased by exercise, and exercise performance is reduced accordingly.
  • Administration group administration of amino acid-containing composition
  • the anti-fatigue effect is so high that the increase in each concentration of is suppressed more than in the non-administration group (non-administration or water administration).
  • the anti-fatigue effect can be evaluated by a self-issued dynamic measurement test.
  • Evaluation by the self-issued dynamic test is, for example, constant exercise load such as forced swimming, treadmill, etc. for the two groups of administration group (administration of amino acid-containing composition) and non-administration group (non-administration or administration of water). It can be evaluated by giving the time, measuring the self-issued amount of movement with the self-issued amount device after the end of the exercise, and comparing these.
  • the self-issued amount of movement can be used as an index of the state in which the exercise performance has been deteriorated due to exercise load, and it can be evaluated that the self-issued amount of movement in the administration group is higher than that in the non-administration group.
  • the anti-fatigue effect in the present invention can be evaluated by VAS (Visual Analog Scale).
  • VAS Visual Analog Scale
  • the evaluation by VAS is, for example, giving exercise load for a certain period of time to two groups of administration group (administration of amino acid-containing composition) and non-administration group (non-administration or administration of water). It can be evaluated by performing VAS on etc. and comparing them.
  • VAS can be subjectively evaluated with respect to fatigue, and it can be evaluated that the anti-fatigue effect is higher as the “fatigue” of the administration group is lower than that of the non-administration group.
  • facilitated lipid metabolism refers to a state where the decomposition of neutral fat into fatty acid and glycerol and the combustion of fatty acid are activated.
  • substances relating to the degradation of neutral fat such as adrenaline, adenylate cyclase, cyclic AMP, protein kinase A, hormone sensitive lipase, or substances relating to ⁇ -oxidation such as acyl CoA synthase and acyl CoA dehydrogenase, Or the state which the substance regarding a citric acid cycle and a mitochondrial electron transport system activated.
  • the lipid metabolism enhancing effect can be evaluated by measuring blood biomarkers.
  • a blood biomarker can be evaluated by measuring, for example, glycerol, blood free fatty acid (non-esterified fatty acid (NEFA), blood ketone body, and the like.
  • Lipid metabolism enhancement effect is, for example, forced exercise, exercise by treadmill or adrenaline administration in two groups, administration group (administration of amino acid-containing composition) and non-administration group (non-administration or water administration). It can be evaluated by giving a state of simulated exercise such as by collecting blood after a certain period of time, measuring the concentrations of the two groups of blood biomarkers, and comparing the measured concentrations.
  • the blood glycerol concentration if the area under the curve (AUC) and the maximum blood concentration (Cmax) of the administration group are higher than those in the non-administration group, it can be evaluated that there is an effect of promoting lipid metabolism.
  • the blood NEFA or blood ketone body concentration in the administration group is higher than that in the non-administration group, it can be evaluated as having an effect of promoting lipid metabolism.
  • the amino acid-containing composition of the present invention may further contain a non-amino acid component having an anti-fatigue and / or lipid metabolism enhancing effect as an active ingredient.
  • the non-amino acid component used as an active ingredient is not particularly limited as long as it has an anti-fatigue effect and / or a lipid metabolism enhancing effect, but is usually a component incorporated in pharmaceuticals and / or foods and drinks, for example, vitamins B1, vitamin B2, vitamin B6, vitamins such as pantothenic acid, vitamins such as CoQ10, carnitine, ⁇ -lipoic acid, minerals such as iron and zinc, glucose, fructose, galactose, mannose sucrose, maltose, lactose, etc.
  • the amino acid-containing composition of the present invention comprises arginine, valine, and serine as active ingredients of amino acids.
  • the amino acid-containing composition of the present invention may contain an ineffective ingredient other than the active ingredient, and the inactive ingredient is used for anti-fatigue and / or for promoting lipid metabolism. Even if it is known, it may be contained as long as it does not act as an active ingredient, for example, its content is small.
  • the inactive ingredient is not particularly limited as long as it can be ingested (administered) into the body, but it is usually a component incorporated in pharmaceuticals and / or foods and drinks, for example, amino acid components such as sodium glutamate and taurine, sucralose , Neotame, acesulfame potassium, thaumatin, stevia extract, licorice extract, rakanka extract, saccharin, saccharin sodium, glycyrrhizin, disodium glycyrrhizinate, trisodium glycyrrhizinate, dihydrochalcone, stevioside, rebaudioside A, etc.
  • amino acid components such as sodium glutamate and taurine, sucralose , Neotame, acesulfame potassium, thaumatin, stevia extract, licorice extract, rakanka extract, saccharin, saccharin sodium, glycyrrh
  • Minerals such as zinc, selenium, iron and copper, carbohydrates such as trehalose, oligosaccharides and rare sugars, useful microorganisms such as lactic acid bacteria, bifidobacteria and propionic acid bacteria and their cultures, royal jelly, collagen, ceramide and glucosamine ,
  • Existing functional materials such as astaxanthin and polyphenol, fragrances, pH adjusters, excipients, acidulants such as citric acid, colorants, emulsifiers, preservatives and the like can be blended.
  • any of L-form, D-form and DL-form can be used, but preferably the L-form. , DL-form, and more preferably L-form.
  • amino acids (1) to (3) and the amino acids that may be contained as inactive ingredients can be used not only in free form but also in amino acid salts.
  • the amino acid salt is not particularly limited as long as it is a pharmaceutical and / or food acceptable amino acid salt of the amino acid (1) to (3) and the amino acid that may be contained as other components. Examples include acid addition salts and salts with bases.
  • acids that form food acceptable salts of amino acids (1) to (3) and amino acids that may be contained as inactive ingredients include hydrochloric acid, hydrogen bromide, sulfuric acid, phosphoric acid, and the like.
  • bases of food-acceptable salts of amino acids (1) to (3) and amino acids that may be contained as inactive ingredients include, for example, inorganic bases such as sodium, potassium, calcium, and ammonia, and ethylenediamine. And organic bases such as propylenediamine, ethanolamine, monoalkylethanolamine, dialkylethanolamine, diethanolamine, and triethanolamine.
  • the amino acids (1) to (3) and the salts of amino acids that may be contained as inactive ingredients may be hydrates (hydrous salts). Examples of such hydrates include 1 to 6 Hydrates are mentioned.
  • the amino acids (1) to (3) and amino acids that may be contained as inactive ingredients are those extracted and purified from animals and plants, microorganisms, etc. containing them, chemical synthesis methods, fermentation methods, genetic recombination. Any of those obtained by law may be used. Commercially available products can be used for the amino acids (1) to (3) and the amino acids that may be contained as inactive ingredients.
  • Each amino acid used in the present invention is preferably a single product with high purity.
  • an amino acid having a purity higher than that prescribed in the “Food Additives Official Document” is used.
  • these amino acids those in the form of physiologically acceptable salts thereof can also be used.
  • the above amino acids may be mixed. Moreover, when manufacturing a solution, what is necessary is just to mix this with distilled water, ethanol, etc., and to melt
  • the method for ingesting (administering) the amino acid-containing composition of the present invention is not limited as long as it can be ingested (administered) into the body.
  • tablets, coated tablets, capsules, granules, powders, solutions, syrups are available.
  • Oral administration with agents, emulsions and the like is preferred.
  • These various preparations are added to the amino acid-containing composition according to the present invention in accordance with conventional methods such as excipients, binders, disintegrants, lubricants, coloring agents, flavoring agents, solubilizing agents, suspending agents, coating agents and the like.
  • it can be formulated using known adjuvants that can be usually used.
  • the anti-fatigue and / or lipid metabolism-promoting food or drink is, for example, a food or drink (food for specified health use, functional display food, nutrition, etc.) by adding a food or drink material and food additive.
  • a food or drink food for specified health use, functional display food, nutrition, etc.
  • functional foods including functional foods such as functional foods, nutritional supplements, other health foods, and supplements.
  • the anti-fatigue and / or lipid metabolism-promoting food and drink of the present invention include, for example, beverages, dairy products such as yogurt, jelly-like products, ice creams, ice confectionery, cookies, gum-like products, powdered products, granules, etc.
  • dairy products such as yogurt, jelly-like products, ice creams, ice confectionery, cookies, gum-like products, powdered products, granules, etc.
  • Product sheet product, capsule product, tablet product, confectionery solid processed food, and the like.
  • food and drink are other than pharmaceutical compositions, and are not particularly limited as long as they are ingestible forms such as solutions, suspensions, emulsions, powders, solid molded products, and the like.
  • dairy products such as milk drinks, yogurts, lactic acid bacteria drinks, fermented milk, ice creams, creams and cheeses; soft drinks, fruit juice drinks, vegetable drinks, soy milk drinks, coffee drinks, tea drinks
  • Beverages such as jelly drinks, cocoa, smoothie powdered drinks and sports powdered drinks, fortified powdered drinks, powdered foods, powdered soups, steamed bread, concentrated drinks, alcoholic drinks; bread, pasta, noodles, Wheat flour products such as cake mix, fried flour, bread crumbs, etc .
  • confectionery such as chocolate, gum, candy, cookies, gummy, snacks, Japanese confectionery, jelly, pudding, etc .
  • the food and drink When used as a food or drink, there are no particular limitations on other ingredients, but the food and drink includes water, protein, carbohydrates, lipids, vitamins, minerals, organic acids, organic bases, fruit juices, and flavors. Etc. can be used as ingredients.
  • proteins include whole milk powder, skim milk powder, partially skimmed milk powder, casein, whey powder, whey protein, whey protein concentrate, whey protein isolate, ⁇ -casein, ⁇ -casein, ⁇ -casein, ⁇ -lactoglobulin , ⁇ -lactalbumin, lactoferrin, soy protein, chicken egg protein, meat protein and other animal and plant proteins, hydrolysates thereof; butter, whey minerals, cream, whey, non-protein nitrogen, sialic acid, phospholipid, lactose, etc.
  • milk-derived components examples include sugars, modified starches (dextrin, soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, and the like.
  • modified starches include animal oils such as lard and fish oil, fractionated oils thereof, hydrogenated oils and transesterified oils; palm oil, safflower oil, corn oil, rapeseed oil, coconut oil, fractionated oils thereof, Examples thereof include vegetable oils such as hydrogenated oils and transesterified oils.
  • vitamins include vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline.
  • minerals include calcium, potassium, magnesium, sodium, copper, iron, manganese, zinc, and selenium.
  • organic acid include malic acid, citric acid, lactic acid, tartaric acid and the like. Two or more of these components can be used in combination, and a synthetic product and / or a food containing a large amount thereof may be used.
  • the anti-fatigue and / or lipid metabolism-promoting food and drink may be packaged, and the container may be selected from plastic, paper, metal, earthenware, or a composite material thereof. Good. It can be made into the form of the container stuffed with these containers. That is, the container-packed food / beverage products and the container-packed pharmaceutical which contain the amino acid containing composition of this invention can be illustrated. Further, the container may be covered with a plastic shrink film, a light-shielding film (for example, a metal foil layer film, a black or dark ink coating film, or the container or the film may be used in combination of two or more kinds.
  • the amino acid-containing composition is preferably combined with a light-shielding container or film from the viewpoint of flavor deterioration and decomposition (reduction) due to light transmission and oxygen transmission.
  • the amino acid-containing composition of the present invention for example, the amino acid-containing composition of the present invention, an anti-fatigue and / or lipid metabolism-enhancing agent, an anti-fatigue and / or lipid metabolism-enhancing food or drink, or an anti-fatigue and lipid
  • the container-packed food or drink for hypermetabolism consists of a unit package form per meal, and contains arginine, valine and serine in the unit package form, and the total intake amount of the amino acids is used for anti-fatigue and / or From the viewpoint of the effect for enhancing lipid metabolism, it is desirable that the amount is adjusted to 0.1 to 50 g, preferably 0.5 to 20 g, and more preferably 1 to 10 g from the viewpoint of being easy to ingest before and during exercise without being a burden.
  • a unit packaging form per meal is a form in which the intake amount per meal is determined in advance, for example, as a food and drink that can be taken orally in a specific amount, not only general foods, It means forms such as beverages (drinks, etc.), health supplements, health functional foods, and supplements.
  • unit packaging form per meal for example, in the case of liquid beverages, gel-like, paste-like or paste-like jelly, powder-like, granule-like, capsule-like, or block-like solid foods, etc.
  • Metal cans, glass bottles (bottles, etc.), plastic containers (e.g., plastic bottles), packs, pouches, film containers, forms such as paper containers, etc. , Dose) can be specified on a packaging container, a homepage, or the like.
  • the amino acid-containing composition of the present invention anti-fatigue and / or lipid metabolism enhancer, anti-fatigue and / or lipid metabolism-enhancing food or drink, or anti-fatigue and lipid metabolism-enhancing container-packed food or drink per day
  • the intake is individually determined based on exercise, age, sex, weight, diet, etc., but the total amount of arginine, valine and serine is, for example, 0.1 to 50 g from the standpoint of exerting more effect.
  • the amount is preferably 0.5 to 25 g, more preferably 1 to 10 g, further preferably 1 to 8 g, further preferably 1 to 6 g, and further preferably 1 to 5 g from the viewpoint of ease of ingestion.
  • the amount is taken before or during exercise.
  • the amino acid-containing composition of the present invention an anti-fatigue and / or lipid metabolism enhancer, an anti-fatigue and / or lipid metabolism-enhancing food or drink, or an anti-fatigue and lipid metabolism-enhanced product
  • Container-packed foods and drinks are labeled with anti-fatigue, increased lipid metabolism, and effective exercise performance, preferably fatigue prevention, fatigue improvement, fatigue reduction, Expected to reduce fatigue, increase lipid metabolism, break down fat, improve lipid metabolism, and improve exercise performance.
  • stamina, improved endurance the body feels light, can stay healthy until the second half of exercise, focus Ideal performance for maintaining strength, reducing physical fatigue, reducing batter, reducing tightness, training well, and enjoying sports (exercise) Performance can be exhibited, comfortably move, or may be displayed attached indicating that the usual such as effective for exceeding the limit of performance.
  • the indication of the present invention is not particularly limited as long as it is given in connection with the anti-fatigue amino acid-containing composition and the amino acid-containing composition for enhancing lipid metabolism.
  • the anti-fatigue amino acid-containing composition A container, packaging material or package insert containing an amino acid-containing composition for enhancing lipid metabolism may be provided with a display / advertisement or the like that the composition is effective.
  • the display of the present invention is a display / advertisement etc. in which the composition is effective for storage media such as flyers, pamphlets, pops, catalogs, posters, books, DVDs, advertisements on electronic bulletin boards, the Internet, etc. It may be attached.
  • the content equivalent to the display of the present invention can be transmitted to a third party by reproduction from a recording medium recorded orally and / or for the purpose of business negotiation and / or sales promotion.
  • the anti-fatigue and / or lipid metabolism-enhancing food or drink or the anti-fatigue and / or lipid metabolism-enhancing container-packed food or drink, the amino acid is used. These may be mixed. Moreover, what is necessary is just to mix and dissolve these in distilled water etc. when making it into a drink.
  • Plasma corticosterone concentration was measured.
  • the blood glucose level was measured with a blood glucose measurement device Breeze 2 (Bayer Pharmaceutical Co., Ltd.).
  • corticosterone was measured by RODEND CORTICOSTERONE ELISA Test Kit (ENDOCRINE TECHNOLOGIES, INC.).
  • the results of blood glucose level and plasma corticosterone concentration were expressed as mean ⁇ standard error.
  • Table 2 shows the average value and standard error of blood glucose level immediately after the end of exercise
  • Table 3 shows the average value and standard error of plasma corticosterone concentration immediately after the end of exercise. It was confirmed that the product of the present invention has a higher anti-fatigue effect than water and conventional products.
  • Example 2 Measurement of plasma glycerol concentration AUC and Cmax (animal study) 24 Wistar male rats were purchased from Japan SLC and acclimated for one week. Rats fasted within 18 hours from the evening before the test. However, water was ad libitum. On the day of the test, the test substance (water, the product A of the present invention (by weight, L-arginine: L-valine: L-serine in an amino acid composition of 18: 11: 1 was added 10 times with water).
  • Diluted product Diluted product
  • product B of the present invention amino acid-containing composition composed of arginine: valine: serine 15: 14: 1 by weight, diluted 10-fold with water
  • conventional product amino acids in Table 1
  • dose 1 g / kg, volume, 10 ml / kg
  • adrenaline 8 ml / Kg was administered intraperitoneally
  • adrenaline was administered to simulate the lipid metabolism during exercise in which adrenaline is secreted by exercise and promotes the breakdown of neutral fat.
  • Example 3 Self-issued dynamic measurement test (animal test) 36 5-week-old SD male rats were purchased from CLEA Japan and acclimated for 2 weeks. Rats were fasted within 18 hours from the evening before the test. However, water was ad libitum. On the day of the test, the test substance (water, the product of the present invention (amino acid-containing composition comprising arginine: valine: serine at a weight ratio of 18: 11: 1) was orally administered to rats. It was simultaneously poured into 45 cm warm water (35 ⁇ 1 ° C.) and allowed to swim for 1 hour.After the exercise, the self-issued exercise amount (cumulative) was measured for 30 minutes with the rat self-issued exercise amount measuring device.
  • the amount of behavior was measured with a rat exercise amount measuring apparatus ACTIMO-10N (Shin Factory Co., Ltd.). The results are shown as mean ⁇ standard error.
  • Table 6 shows the average value and standard error of the self-issued amount of movement after exercise. It was confirmed that the product of the present invention has a high anti-fatigue effect because the self-issued amount of movement for 30 minutes after exercise is 50 higher than that of water.
  • Anti-fatigue effect enhancement test human test
  • the test subjects were healthy men in their 20s and 30s.
  • the study design was a double blind crossover study.
  • a test food was ingested once, and after 30 minutes, an endurance exercise load test using a bicycle ergometer (Aerobike (registered trademark) 75XLIII (Konami Sports & Life Co., Ltd.)) was performed.
  • As for the exercise load condition exercise for 40 minutes with an exercise load corresponding to 50% of VO2max of each subject was repeated twice with a 3-minute break.
  • the test food is a product of the present invention (amino acid-containing composition comprising arginine: valine: serine 18: 11: 1 by weight) 5 capsules containing 3000 mg or an amino acid-containing composition that does not contain amino acids. 5 capsules (control product) whose presence or absence could not be identified were used.
  • blood was collected at rest, before exercise load, after exercise load end, after 30 minutes, and after 60 minutes, and blood cortisol concentration was measured from the obtained blood.
  • the average value of the blood cortisol concentration change amount from before the exercise load to after the end of the exercise load is shown in FIG. 1 (15 effective analysis subjects). It was confirmed that the product of the present invention has a significantly lower blood cortisol concentration than the control and has an anti-fatigue effect.
  • Example 5 Comparison test of muscle tension and dullness (human test) Subjects were healthy male athletes in their 20s. We conducted lifestyle questionnaires and physical measurements as pre-examinations, selected subjects, and then conducted this study. The study design was a double blind crossover study. In this test, the test food was ingested once and arbitrary exercise was performed after 30 minutes. Test foods are 5 capsules encapsulating 3000 mg of the product of the present invention (amino acid-containing composition composed of arginine: valine: serine 18: 11: 1 by weight) or conventional products (amino acids in Table 1: 3000 mg, carnitine) : 200 mg, CoQ10: 30 mg) was used.
  • amino acid-containing composition composed of arginine: valine: serine 18: 11: 1 by weight
  • conventional products as amino acids in Table 1: 3000 mg, carnitine
  • VAS Vehicle Analog Scale
  • Example 6 Fatigue experience test (human test) Subjects were healthy male athletes in their 20s. We conducted lifestyle questionnaires and physical measurements as pre-examinations, selected subjects, and then conducted this study. The study design was a double blind crossover study. In this test, the test food was ingested once and arbitrary exercise was performed after 30 minutes. Test foods include 5 capsules containing 1300 mg of the present invention product (amino acid-containing composition composed of 18: 11: 1 arginine: valine: serine by weight) or 3000 mg of conventional products (amino acids in Table 1). 5 capsules were used. In addition, VAS (Visual Analog Scale) was performed before and after exercise.
  • VAS Visual Analog Scale
  • Table 8 shows the average value and standard error of the VAS change amount from before the exercise load to after the end of the exercise load (18 effective analysis subjects). Despite the fewer types and amounts of amino acids than the conventional product, the product of the present invention has a low “feeling of fatigue” and was confirmed to have an anti-fatigue effect.
  • Example 7 Preservability of amino acid-containing composition L-arginine 1800 mg, L-valine 1100 mg, and L-serine 100 mg were filled into cellulose white capsule 00 to produce a capsule containing an amino acid-containing composition and filled into an aluminum pouch container. The amino acid-containing composition in the capsule after 2 weeks of storage at room temperature was retained without being degraded (decreased).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PCT/JP2017/005825 2016-02-19 2017-02-17 アミノ酸含有組成物 WO2017142052A1 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201780011660.1A CN108697679B (zh) 2016-02-19 2017-02-17 含氨基酸的组合物
JP2018500217A JP6942113B2 (ja) 2016-02-19 2017-02-17 アミノ酸含有組成物
HK18114133.9A HK1255012A1 (zh) 2016-02-19 2018-11-06 含氨基酸的組合物

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2016-029749 2016-02-19
JP2016029749 2016-02-19
JP2016-103402 2016-05-24
JP2016103402 2016-05-24

Publications (1)

Publication Number Publication Date
WO2017142052A1 true WO2017142052A1 (ja) 2017-08-24

Family

ID=59626193

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/005825 WO2017142052A1 (ja) 2016-02-19 2017-02-17 アミノ酸含有組成物

Country Status (4)

Country Link
JP (1) JP6942113B2 (zh)
CN (1) CN108697679B (zh)
HK (1) HK1255012A1 (zh)
WO (1) WO2017142052A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019022216A1 (ja) * 2017-07-28 2019-01-31 株式会社明治 筋力向上用アミノ酸組成物
KR102235563B1 (ko) * 2020-08-26 2021-04-02 (주)이삼오구 고함량 아르기닌을 포함하는 피로회복 및 성기능 개선용 조성물

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111296843A (zh) * 2020-03-03 2020-06-19 上海泓商生物科技有限公司 抗疲劳、运动型益生菌

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102321A1 (ja) * 2004-04-19 2005-11-03 Kirin Beer Kabushiki Kaisha 糖新生によりアルコール代謝を促進又は疲労を改善する組成物
JP2006193496A (ja) * 2005-01-17 2006-07-27 Ozeki Corp 液化酒粕を再発酵して得られる機能性素材
JP2007161675A (ja) * 2005-12-16 2007-06-28 Taisho Pharmaceut Co Ltd 疲労改善内服剤
WO2008105368A1 (ja) * 2007-02-28 2008-09-04 Meiji Dairies Corporation アミノ酸組成物
WO2015022962A1 (ja) * 2013-08-14 2015-02-19 株式会社明治 脂質代謝促進剤
JP2015181399A (ja) * 2014-03-24 2015-10-22 アサヒ飲料株式会社 ヘスペリジン含有飲料、苦味改善剤及び苦味改善方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005102321A1 (ja) * 2004-04-19 2005-11-03 Kirin Beer Kabushiki Kaisha 糖新生によりアルコール代謝を促進又は疲労を改善する組成物
JP2006193496A (ja) * 2005-01-17 2006-07-27 Ozeki Corp 液化酒粕を再発酵して得られる機能性素材
JP2007161675A (ja) * 2005-12-16 2007-06-28 Taisho Pharmaceut Co Ltd 疲労改善内服剤
WO2008105368A1 (ja) * 2007-02-28 2008-09-04 Meiji Dairies Corporation アミノ酸組成物
WO2015022962A1 (ja) * 2013-08-14 2015-02-19 株式会社明治 脂質代謝促進剤
JP2015181399A (ja) * 2014-03-24 2015-10-22 アサヒ飲料株式会社 ヘスペリジン含有飲料、苦味改善剤及び苦味改善方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019022216A1 (ja) * 2017-07-28 2019-01-31 株式会社明治 筋力向上用アミノ酸組成物
KR102235563B1 (ko) * 2020-08-26 2021-04-02 (주)이삼오구 고함량 아르기닌을 포함하는 피로회복 및 성기능 개선용 조성물

Also Published As

Publication number Publication date
CN108697679B (zh) 2021-08-31
JP6942113B2 (ja) 2021-09-29
CN108697679A (zh) 2018-10-23
HK1255012A1 (zh) 2019-08-02
JPWO2017142052A1 (ja) 2018-12-13

Similar Documents

Publication Publication Date Title
JP5876205B2 (ja) Ｄ−ソルボースからなる甘味料におけるｄ−ソルボースの甘味の不足や、甘味の持続を改良する方法
US20110039767A1 (en) Food compositions
JP2006223293A (ja) ダイエット食品組成物
US20160367529A1 (en) Debility preventative
JP6942113B2 (ja) アミノ酸含有組成物
TWI773739B (zh) 用以促進體內ｂｄｎｆ量增加之組成物
JP2013227228A (ja) 筋肉増加剤
JP2006273850A (ja) 血中乳酸値上昇抑制組成物及びそれを含有する飲食品
JPWO2017026429A1 (ja) 筋肉合成促進剤
WO2009154280A1 (ja) 過食防止剤
Jusoh et al. Evaluation of nutritive values and consumer acceptance of sweet corn (Zea mays) juice as a recovery beverage for exercising people
JP2017523183A5 (zh)
WO2010025335A2 (en) Functional consumable compositions for promoting skin health and methods for using the same
JP6753618B2 (ja) 血中中性脂肪上昇抑制組成物
JP2007031403A (ja) 乳酸産生抑制剤
JP2020186264A (ja) 血中中性脂肪上昇抑制組成物
JP4847732B2 (ja) 冷え症改善剤
TW201909891A (zh) 用於促進正腎上腺素分泌之胺基酸組合物
JP2013124222A (ja) 内臓脂肪低減剤
WO2019022216A1 (ja) 筋力向上用アミノ酸組成物
JP6646369B2 (ja) 抗疲労剤
JP7462338B2 (ja) 抗疲労剤
JP6829487B2 (ja) 抗疲労剤
JP7083254B2 (ja) β－ヒドロキシ－β－メチル酪酸カルシウム塩（ＨＭＢＣａ）の苦味が低減された飲食品組成物
Bosch et al. Nutrition for Endurance and Ultra‐Endurance Training

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17753307

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2018500217

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17753307

Country of ref document: EP

Kind code of ref document: A1